To determine the effect of anthelmintic treatment on the pro-inflammatory chemokine milieu in T2DM, we measured the plasma levels of CCL1, CCL2, CCL3, CCL11, CXCL1, CXCL2, CXCL9, CXCL10 and CXCL11 in Ss+ individuals before (pre-T) and 6 months after anthelmintic treatment (post-T). This evidence concerns the gene CXCL9 and type 2 diabetes mellitus.